You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

CLINICAL TRIALS PROFILE FOR UROLOGIC G IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Urologic G In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003930 ↗ Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed National Cancer Institute (NCI) Phase 1/Phase 2 1999-09-01 RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
NCT00003930 ↗ Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed Radiation Therapy Oncology Group Phase 1/Phase 2 1999-09-01 RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
NCT00132301 ↗ Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma Completed Sanofi Phase 3 2006-06-01 VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy.
NCT00132301 ↗ Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma Completed VA Office of Research and Development Phase 3 2006-06-01 VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy.
NCT00138008 ↗ Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy Completed Ministry of Health, Labour and Welfare, Japan Phase 3 2004-05-01 The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in comparison with endocrine therapy alone for PSA failure after radical prostatectomy.
NCT00138008 ↗ Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy Completed Haruhiko Fukuda Phase 3 2004-05-01 The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in comparison with endocrine therapy alone for PSA failure after radical prostatectomy.
NCT00148083 ↗ Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia Completed Janssen, LP Phase 3 2005-09-01 The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training. The hypothesis guiding this study is that Risperdal Consta, by improving verbal memory, will improve the ability to benefit from skills training interventions among schizophrenia patients. The primary objective of this study is to compare patients on Risperdal Consta to patients on other atypical antipsychotic medications in terms of their ability to benefit from skills training interventions. A secondary objective of this study is to determine whether patients taking Risperdal Consta improve in other areas of cognitive functioning and social functioning.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Urologic G In Plastic Container

Condition Name

Condition Name for Urologic G In Plastic Container
Intervention Trials
Prostate Cancer 9
Bladder Cancer 6
Pain, Postoperative 6
Urologic Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Urologic G In Plastic Container
Intervention Trials
Pain, Postoperative 14
Urinary Bladder Neoplasms 10
Syndrome 7
Prostatic Neoplasms 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Urologic G In Plastic Container

Trials by Country

Trials by Country for Urologic G In Plastic Container
Location Trials
United States 215
Japan 25
Canada 19
Korea, Republic of 8
Egypt 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Urologic G In Plastic Container
Location Trials
New York 14
California 13
Texas 10
Michigan 10
Maryland 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Urologic G In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Urologic G In Plastic Container
Clinical Trial Phase Trials
Phase 4 45
Phase 3 18
Phase 2 15
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Urologic G In Plastic Container
Clinical Trial Phase Trials
Completed 52
Recruiting 21
Not yet recruiting 17
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Urologic G In Plastic Container

Sponsor Name

Sponsor Name for Urologic G In Plastic Container
Sponsor Trials
National Cancer Institute (NCI) 4
University of Texas Southwestern Medical Center 4
Yonsei University 4
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Urologic G In Plastic Container
Sponsor Trials
Other 154
Industry 26
NIH 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.